Zimeldine induced neuropathies.
Zimeldine is recently-introduced antidepressant drug. It has a novel pyridylallylamine structure and acts by selective inhibition of 5-hydroxytryptamine re-uptake at central nerve synapses. This communication reports 2 patients who developed neuropathies within 1 week of starting treatment with this drug. This has hitherto not been described.